LKFT logo

LAKEFRONT BIOTHERAPEUTIC-ADR

LKFTNASDAQ
πŸ† #1771 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track LKFT
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.18B
Small Cap
πŸ“ˆRevenue Growth (YoY)
303.5%
High Growth
πŸ“ŠGross Margin
98.0%
High
πŸ’΅FCF Margin
-28.9%
Thin
βš–οΈP/S Ratio
1.9x
Cheap
Otter Score
80
Strong
No chart data available for LKFT.

Trading Snapshot

Day Range
β€”
52-Week Range
$25.68 – $36.24
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
65.5M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$1.11B
Last Q Revenue
$12M
P/E Ratio
4.1
P/S Ratio
1.9x
EPS (TTM)
$7.42
Dividend Yield
0.00%
Dilution (1yr)
+220749.3%
LKFT logo

LAKEFRONT BIOTHERAPEUTIC-ADR

LKFT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1Bβ–² +303.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.3%β–² +11.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$501Mβ–Ό βˆ’366.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
65.9Mβ–² +220749.3% YoY
StockOtter Β· stockotter.space

About LAKEFRONT BIOTHERAPEUTIC-ADR

Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100
Analyst data unavailable.

Latest News & Updates

News unavailable.